
    
      PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are
      randomized to treatment with low dose intravenous immunoglobulin (IVIg), high dose IVIg, or
      placebo.

      Patients must first complete baseline evaluation. Patients receive IVIg or placebo on days 1,
      2, 3, and 5, biweekly at weeks 2-4, weekly at weeks 5-8, and every other week at weeks 9-12.

      Patients are assessed at 6, 12, 36, 52, and 104 weeks.

      Completion date provided represents the completion date of the grant per OOPD records
    
  